target identification

A generic term for any method used to identify a molecular species of interest—e.g., hybridisation, or the use of siRNA (small interfering) RNA to silence target genes.

References in periodicals archive ?

This Decision Resources report explores both state-of-the-art and emerging target identification and validation technologies and methods.

A wide array of target identification technologies is available, including genomics, gene expression profiling, and proteomics.

Emerging Technologies such as RNAi and Metabolic Profiling Hold a Great Deal of Promise for Improving the Efficiency and Efficacy of Drug Target Validation

Although model-oriented KBs are currently used for target identification and validation, researchers are likely to find high-value uses in areas such as lead compound selection, toxicology, and clinical development.

Model-Oriented Knowledgebases (KBs) Can Accelerate the Drug Discovery Process by Reducing the Time Spent on These Processes

HighQ supports HD research aimed at target identification and validation, the development and use of animal models, drug delivery and the search for markers of disease progression.

Proteome Systems and HighQ Foundation Announce the Discovery of Prognostic and Diagnostic Markers for Neurodegenerative Disease; Two-Year Human Study Launched to Validate Markers and Enable Rapid Drug Development

FSMA and Invitrogen have agreed that success in the initial target identification stages would be followed by further collaborative work to validate the targets and develop new compound screening assays.

FSMA And Invitrogen Partner to Investigate Molecular Mechanisms of Spinal Muscular Atrophy

In 2005, HTS laboratories continue to take on more responsibility in drug discovery, with some expanding into target identification and validation, as well as in vitro ADME/Tox and lead optimization areas.

High Throughput Screening: Steadily Increasing Success in Drug Discovery, According to HighTech Business Decisions

NexGenix has integrated all aspects of drug development for NF1 and NF2, from target identification to the clinic.